Literature DB >> 20050688

Quantitative proteomic analysis reveals the perturbation of multiple cellular pathways in HL-60 cells induced by arsenite treatment.

Lei Xiong1, Yinsheng Wang.   

Abstract

Arsenic is ubiquitously present in the environment; it is a known human carcinogen and paradoxically it is also a successful drug for the clinical remission of acute promyelocytic leukemia (APL). The cellular responses induced by arsenite treatment have been investigated for years; however, the precise mechanisms underlying its cytotoxicity and therapeutic activity remain unclear. Here we report the use of mass spectrometry together with stable isotope labeling by amino acids in cell culture (SILAC) for the comparative study of protein expression in HL-60 cells that were untreated or treated with a clinically relevant concentration of arsenite. Our results revealed that, among the 1067 proteins quantified in both forward and reverse SILAC measurements, 56 had significantly altered levels of expression induced by arsenite treatment. These included the up-regulation of core histones, neutrophil elastase, alpha-mannosidase as well as the down-regulation of fatty acid synthase and protein phosphatase 1 alpha. We further demonstrated that the arsenite-induced growth inhibition of HL-60 cells could be rescued by treatment with palmitate, the final product of fatty acid synthase, supporting that arsenite exerts its cytotoxic effect, in part, via suppressing the expression of fatty acid synthase and inhibiting the endogenous production of fatty acid. The results from the present study offered important new knowledge for gaining insights into the molecular mechanisms of action of arsenite.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20050688      PMCID: PMC2819029          DOI: 10.1021/pr9011359

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  54 in total

1.  Expression clustering reveals detailed co-expression patterns of functionally related proteins during B cell differentiation: a proteomic study using a combination of one-dimensional gel electrophoresis, LC-MS/MS, and stable isotope labeling by amino acids in cell culture (SILAC).

Authors:  Edwin P Romijn; Chantal Christis; Marnix Wieffer; Joost W Gouw; Asier Fullaondo; Peter van der Sluijs; Ineke Braakman; Albert J R Heck
Journal:  Mol Cell Proteomics       Date:  2005-06-15       Impact factor: 5.911

2.  Lysosomes and trivalent arsenic treatment in acute promyelocytic leukemia.

Authors:  Sutisak Kitareewan; B D Roebuck; Eugene Demidenko; Roger D Sloboda; Ethan Dmitrovsky
Journal:  J Natl Cancer Inst       Date:  2007-01-03       Impact factor: 13.506

Review 3.  Fatty acid synthase and cancer: new application of an old pathway.

Authors:  Francis P Kuhajda
Journal:  Cancer Res       Date:  2006-06-15       Impact factor: 12.701

Review 4.  Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies.

Authors:  Dan Douer; Martin S Tallman
Journal:  J Clin Oncol       Date:  2005-04-01       Impact factor: 44.544

5.  Sodium arsenite-induced inhibition of eukaryotic translation initiation factor 4E (eIF4E) results in cytotoxicity and cell death.

Authors:  Sreekumar Othumpangat; Michael Kashon; Pius Joseph
Journal:  Mol Cell Biochem       Date:  2005-11       Impact factor: 3.396

Review 6.  Arsenic, internal cancers, and issues in inference from studies of low-level exposures in human populations.

Authors:  Kenneth P Cantor; Jay H Lubin
Journal:  Toxicol Appl Pharmacol       Date:  2007-02-24       Impact factor: 4.219

7.  Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia.

Authors:  Pei-Zheng Zheng; Kan-Kan Wang; Qun-Ye Zhang; Qiu-Hua Huang; Yan-Zhi Du; Qing-Hua Zhang; Da-Kai Xiao; Shu-Hong Shen; Sandrine Imbeaud; Eric Eveno; Chun-Jun Zhao; Yu-Long Chen; Hui-Yong Fan; Samuel Waxman; Charles Auffray; Gang Jin; Sai-Juan Chen; Zhu Chen; Ji Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-13       Impact factor: 11.205

8.  The fatty acid synthase gene is a conserved p53 family target from worm to human.

Authors:  Anna Maria D'Erchia; Apollonia Tullo; Konstantinos Lefkimmiatis; Cecilia Saccone; Elisabetta Sbisà
Journal:  Cell Cycle       Date:  2006-04-01       Impact factor: 4.534

9.  Comparing SILAC and two-dimensional gel electrophoresis image analysis for profiling urokinase plasminogen activator signaling in ovarian cancer cells.

Authors:  Pauliina M Uitto; Braddon K Lance; Graham R Wood; James Sherman; Mark S Baker; Mark P Molloy
Journal:  J Proteome Res       Date:  2007-05-02       Impact factor: 4.466

10.  Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1.

Authors:  Eiji Furuta; Sudha K Pai; Rui Zhan; Sucharita Bandyopadhyay; Misako Watabe; Yin-Yuan Mo; Shigeru Hirota; Sadahiro Hosobe; Taisei Tsukada; Kunio Miura; Shuichi Kamada; Ken Saito; Megumi Iiizumi; Wen Liu; Johan Ericsson; Kounosuke Watabe
Journal:  Cancer Res       Date:  2008-02-15       Impact factor: 12.701

View more
  12 in total

1.  Quantitative proteomic analysis revealed lovastatin-induced perturbation of cellular pathways in HL-60 cells.

Authors:  Xiaoli Dong; Yongsheng Xiao; Xinning Jiang; Yinsheng Wang
Journal:  J Proteome Res       Date:  2011-10-21       Impact factor: 4.466

2.  SILAC-Based Quantitative Proteomic Analysis Unveils Arsenite-Induced Perturbation of Multiple Pathways in Human Skin Fibroblast Cells.

Authors:  Fan Zhang; Yongsheng Xiao; Yinsheng Wang
Journal:  Chem Res Toxicol       Date:  2017-02-14       Impact factor: 3.739

3.  Proteomic analysis of energy metabolism and signal transduction in irradiated melanoma cells.

Authors:  Lu-Bin Yan; Kai Shi; Zhi-Tong Bing; Yi-Lan Sun; Yang Shen
Journal:  Int J Ophthalmol       Date:  2013-06-18       Impact factor: 1.779

4.  Clinical proteomics of myeloid leukemia.

Authors:  Sigrun M Hjelle; Rakel B Forthun; Ingvild Haaland; Håkon Reikvam; Gry Sjøholt; Oystein Bruserud; Bjørn T Gjertsen
Journal:  Genome Med       Date:  2010-06-29       Impact factor: 11.117

5.  Quantitative analysis of the secretome of TGF-beta signaling-deficient mammary fibroblasts.

Authors:  Baogang J Xu; Wenwei Yan; Bojana Jovanovic; Angel Q An; Nikki Cheng; Mary E Aakre; Yajun Yi; Jimmy Eng; Andrew J Link; Harold L Moses
Journal:  Proteomics       Date:  2010-07       Impact factor: 3.984

6.  Quantification of oxidative DNA lesions in tissues of Long-Evans Cinnamon rats by capillary high-performance liquid chromatography-tandem mass spectrometry coupled with stable isotope-dilution method.

Authors:  Jin Wang; Bifeng Yuan; Candace Guerrero; Ralf Bahde; Sanjeev Gupta; Yinsheng Wang
Journal:  Anal Chem       Date:  2011-02-16       Impact factor: 6.986

7.  Quantitative proteomic analysis reveals the perturbation of multiple cellular pathways in jurkat-T cells induced by doxorubicin.

Authors:  Xiaoli Dong; Lei Xiong; Xinning Jiang; Yinsheng Wang
Journal:  J Proteome Res       Date:  2010-09-23       Impact factor: 4.466

8.  Quantitative proteomic analysis revealed N'-nitrosonornicotine-induced down-regulation of nonmuscle myosin II and reduced cell migration in cultured human skin fibroblast cells.

Authors:  John M Prins; Yinsheng Wang
Journal:  J Proteome Res       Date:  2013-01-28       Impact factor: 4.466

9.  Gut microbiome perturbations induced by bacterial infection affect arsenic biotransformation.

Authors:  Kun Lu; Peter Hans Cable; Ryan Phillip Abo; Hongyu Ru; Michelle E Graffam; Katherine Ann Schlieper; Nicola M A Parry; Stuart Levine; Wanda M Bodnar; John S Wishnok; Miroslav Styblo; James A Swenberg; James G Fox; Steven R Tannenbaum
Journal:  Chem Res Toxicol       Date:  2013-11-18       Impact factor: 3.739

10.  Comparative proteomics in acute myeloid leukemia.

Authors:  Magdalena Luczak; Maciej Kaźmierczak; Luiza Hadschuh; Krzysztof Lewandowski; Mieczysław Komarnicki; Marek Figlerowicz
Journal:  Contemp Oncol (Pozn)       Date:  2012-05-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.